NCT01455883View on ClinicalTrials.gov

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Type 2 Diabetes
Interventions
DRUG

ITCA 650 60 mcg/day

exenatide in DUROS

DRUG

glimepiride

oral glimepiride does-escalated,if tolerated, to 8 mg/day

Trial Locations (1)

94545

Intarcia Therapeutics, Inc, Hayward

Sponsors
All Listed Sponsors
lead

Intarcia Therapeutics

INDUSTRY